Therefore, this retrospective study suggested that long-acting GLP-1 RAs used for at least 6 months and up to 2 years can provide significant benefits (such as weight loss and improvement in glucose control) in patients with long-standing T1D, without being associated with an increased incidence of hypoglycemia or DKA [111]. The gene discussed is GCG; the disease is type 1 diabetes mellitus.